LIVN - LivaNova PLC

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
79.23
-2.33 (-2.86%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close81.56
Open81.12
Bid0.00 x 800
Ask0.00 x 1000
Day's Range78.28 - 82.87
52 Week Range64.80 - 126.99
Volume274,360
Avg. Volume376,967
Market Cap3.834B
Beta (3Y Monthly)0.39
PE Ratio (TTM)N/A
EPS (TTM)-5.41
Earnings DateOct 29, 2019 - Nov 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est92.29
Trade prices are not sourced from all markets
  • Business Wire

    LivaNova to Present Updates on Autonomic Regulation Therapy at the 23rd Annual Scientific Meeting of the Heart Failure Society of America

    LivaNova PLC , a market-leading medical technology and innovation company, today announced it will present a summary of implantable neuromodulation technology for patients with heart failure during the 23rd Annual Scientific Meeting of the Heart Failure Society of America, September 13 – 16, Pennsylvania Convention Center, Philadelphia.

  • LivaNova's (LIVN) Study to Evaluate VNS Therapy Gets CMS Nod
    Zacks

    LivaNova's (LIVN) Study to Evaluate VNS Therapy Gets CMS Nod

    LivaNova (LIVN) is aiming to reach out to more patients, with improved enrollment program.

  • Business Wire

    LivaNova Receives Approval from U.S. Centers for Medicare & Medicaid Services for RECOVER Clinical Study

    LivaNova PLC (LIVN), a market-leading medical technology and innovation company, today announced the U.S. Centers for Medicare & Medicaid Services (CMS) accepted the LivaNova protocol for “A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression” (RECOVER). In February, CMS modified the National Coverage Determination (NCD) from non-coverage to a Coverage with Evidence Development (CED) framework in which CMS will cover the LivaNova Vagus Nerve Stimulation Therapy (VNS Therapy) for Medicare beneficiaries enrolled in the approved study.

  • Did LivaNova PLC (NASDAQ:LIVN) Insiders Sell Shares?
    Simply Wall St.

    Did LivaNova PLC (NASDAQ:LIVN) Insiders Sell Shares?

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

  • Business Wire

    LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2019

    LivaNova PLC , a market-leading medical technology and innovation company, today announced it will present two abstracts further establishing the viability of implantable neuromodulation technology to treat patients with heart failure during the European Society of Cardiology Congress 2019 from August 31 to September 4 in Paris.

  • LivaNova PLC (LIVN) Q2 2019 Earnings Call Transcript
    Motley Fool

    LivaNova PLC (LIVN) Q2 2019 Earnings Call Transcript

    LIVN earnings call for the period ending June 30, 2019.

  • LivaNova (LIVN) Q2 Earnings and Revenues Surpass Estimates
    Zacks

    LivaNova (LIVN) Q2 Earnings and Revenues Surpass Estimates

    LivaNova (LIVN) delivered earnings and revenue surprises of 2.94% and 1.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Medical Products' Earnings Roster for Jul 31: MCK, HOLX & More
    Zacks

    Medical Products' Earnings Roster for Jul 31: MCK, HOLX & More

    Solid growth in emerging markets is expected to be an added positive this earnings season.

  • Analysts Estimate LivaNova (LIVN) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate LivaNova (LIVN) to Report a Decline in Earnings: What to Look Out for

    LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Is There An Opportunity With LivaNova PLC's (NASDAQ:LIVN) 25% Undervaluation?
    Simply Wall St.

    Is There An Opportunity With LivaNova PLC's (NASDAQ:LIVN) 25% Undervaluation?

    Today we will run through one way of estimating the intrinsic value of LivaNova PLC (NASDAQ:LIVN) by taking the...

  • Here’s What Hedge Funds Think About LivaNova PLC (LIVN)
    Insider Monkey

    Here’s What Hedge Funds Think About LivaNova PLC (LIVN)

    It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]

  • Business Wire

    LivaNova Welcomes Stacy Enxing Seng to Board of Directors

    LivaNova PLC , a market-leading medical technology company, today announced that Stacy Enxing Seng, a Venture Partner with Lightstone Ventures and former executive at several healthcare and medical technology companies, was elected by the Company’s shareholders to join its Board of Directors during its June 18 annual general meeting.

  • Business Wire

    LivaNova to Host Conference Call for Second Quarter 2019 Results

    LivaNova PLC (LIVN), a market-leading medical technology company, will host a conference call to discuss its second quarter 2019 results on Wednesday, July 31, 2019 at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its second quarter 2019 results prior to the call. A live webcast of the conference call will be available on the Investor Relations section of the LivaNova website at www.livanova.com.

  • Markit

    See what the IHS Markit Score report has to say about LivaNova PLC.

    LivaNova PLC NASDAQ/NGS:LIVNView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for LIVN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding LIVN totaled $420 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Business Wire

    LivaNova to Present at the UBS Global Healthcare Conference

    LivaNova PLC (LIVN), a market-leading medical technology company, today announced Damien McDonald, Chief Executive Officer, and Thad Huston, Chief Financial Officer, will present at the UBS Global Healthcare Conference on Wednesday, May 22 in New York at 10 a.m. Eastern Time. LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world.

  • Business Wire

    New Data Emphasizing LivaNova Perceval Valve Durability to be Presented at the American Association for Thoracic Surgery Meeting

    LivaNova PLC (LIVN), a market-leading medical technology company, today announced that new clinical data for its sutureless surgical aortic valve, Perceval®, will be unveiled at this year’s American Association for Thoracic Surgery (AATS) meeting. On May 4, Prof. Bart Meuris from Leuven University Hospital (BE) will present the data from his center’s 11-year clinical experience with Perceval, which represents the longest clinical follow-up for the valve that has been published. Of particular significance in the findings is the absence of explants due to structural valve deterioration (SVD), as well as the low rate of paravalvular leak (PVL) reported.

  • Livanova (LIVN) Q1 2019 Earnings Call Transcript
    Motley Fool

    Livanova (LIVN) Q1 2019 Earnings Call Transcript

    LIVN earnings call for the period ending March 31, 2019.

  • Associated Press

    LivaNova: 1Q Earnings Snapshot

    On a per-share basis, the London-based company said it had a loss of 31 cents. Earnings, adjusted for non-recurring costs and amortization costs, were 54 cents per share. The results exceeded Wall Street ...

  • Business Wire

    LivaNova Reports First Quarter 2019 Results

    LivaNova PLC , a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2019.